For most asthma patients, inhaled steroids and bronchodilators work. But 5‑10% have severe, uncontrolled asthma despite maximum therapy. Enter biologics — monoclonal antibodies that block specific inflammatory pathways. The India respiratory drugs market forecast predicts that biologics will be a major growth driver in the next decade, as patents expire and local manufacturers (like Biocon and Cipla) launch affordable biosimilars.

What's available? Omalizumab (anti‑IgE), mepolizumab (anti‑IL5), dupilumab (anti‑IL4/13). They're given by injection every 2‑4 weeks and can dramatically reduce exacerbations and steroid use. The India respiratory drugs market analysis notes that the main barrier is cost — imported biologics cost ₹1‑2 lakh per month, out of reach for most. But biosimilars could cut prices by 80%.

However, biologics are not first‑line. They're for patients who have failed other therapies and have specific biomarkers (e.g., high eosinophils). Overprescribing would be a waste of money and resources.

The message: if you have severe asthma that's not controlled, ask your pulmonologist about biologic therapy. It could be life‑changing — but only if you're the right candidate.